Randomized Double Blind Trial to Compare the Efficacy of Granisetron And Ondansetron in Controlling Emesis in Children with Acute Lymphoblastic Leukemia

Siddique, Rahmat Ullah; Hafiz, Golam; Jamal, Chowdhury Yakub; Islam, Aminul; Alia, Reema Afroza

doi:10.3329/bjch.v36i3.14272

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A double-blind, randomized study by Siddique et al reported that complete and partial responses to CINV in ondansetron administration alone were 70% and 30%, respectively, for the acute type, and 43% and 50%, respectively, for the delayed type. 31 Jaing et al reported that administration of 0.15 mg/kg ondansetron gave a complete response of 45.5%. 7 In addition, Holdsworth et al reported that complete response to ondansetron (0.45 mg/kg IV) was seen in 65.5% of patients.…”

Section: Discussionmentioning

confidence: 99%

The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients

Simbolon

Nafianti

Sianturi

et al. 2018

View full text Add to dashboard Cite

Background Chemotherapy-induced nausea and vomiting are some of the most disturbing side effects in pediatric cancer patients. The standard recommendation is the use of 5-hydroxytryptamine 3 receptor antagonist, such as ondansetron, to treat these symptoms. Despite this treatment, more than 50% of patients still experience nausea and vomiting.Objective To evaluate the effect of the addition of omeprazole to ondansetron in the treatment of chemotherapy-induced nausea and vomiting.Methods A double-blind, randomized, controlled trial was conducted at Haji Adam Malik Hospital, Medan, North Sumatera, from March to May 2016. Subjects were children aged 1 to 18 years, diagnosed with cancer, and who received intravenous chemotherapy. Patients were randomized to receive either a single dose of ondansetron (0.5 mg/kg) plus placebo or ondansetron (0.5 mg/kg) plus omeprazole (0.5 mg/kg). The severity of nausea and vomiting were measured using the Rhodes index of nausea, vomiting, and retching during the 24 hours after initiation of emetogenic chemotherapy. The primary outcome of efficacy was the proportion of patients who achieved complete response (lack of nausea/vomiting). Statistical analysis was performed by Chi-square and Fischer’s exact tests.Results Seventy eligible pediatric patients were randomized into two groups: 32 subjects in the ondansetron + placebo group and 38 others in the ondansetron + omeprazole group. The therapy failed in 50% (16/32) of the ondansetron + placebo group and 18.4% (7/38) of the ondansetron + omeprazole group. There was a significant difference in the clinical response between groups (P=0.01).Conclusion The addition of omeprazole to ondansetron for the treatment of chemotherapy-induced nausea and vomiting is more effective than administration of ondansetron alone.

show abstract

Section: Discussionmentioning

confidence: 99%

The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients

Simbolon

Nafianti

Sianturi

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It corresponds to Siddique R et al, who observed nausea in 36.6% of children's (4-10 years) within 48 hours of HD-MTX infusion. [12] Another study with reference to Vaishnavi K et al, who observed vomiting in 53% patients younger than 15 years. [8] It also corresponds to the study of Rask C et al, who observed nausea/vomiting in 28.25 of patients.…”

Section: Population Descriptionmentioning

confidence: 97%

A Retrospective Analysis of Toxicity Profile in Pediatric Patients with all Receiving High Dose Methotrexete

Ruman¹

2019

jmscr

View full text Add to dashboard Cite

Aims and Objectives: Our aim was to document the toxicity profile in Acute Lymphoblastic Leukemia in pediatric patients who received only chemotherapeutic agent i.e. High Dose Methotrexate in their consolidation phase of their treatment plan. Method: A Retrospective study was carried out in the inpatient department of Aware Gleneagles Global Hospital, Hyderabad, India. A total of 100 pediatric in patients with Acute Lymphoblastic Leukemia from the age of 1-18 years in their Consolidation phase consisting of 4 cycles each containing a course of HDMTX from 2017-2018 were included in the study. All information significant to the study was collected from the Patient case sheets and Electronic medical records in the designed patient's proforma or data collection form which includes Patient demographic details, Laboratory values etc. The information was also retrieved by the telephonic conversation with the patient or patient's representative. Results: In our study mean age was found to be 7.07 ± 4.520.We found that there was high incidence rate in males (67%) than females (33).We observed pediatric patients effected with adverse effects such as nausea and Vomiting (25%), Mucositis (13%), Neutropenia (5%), Anemia (55%), Thrombocytopenia (27%) and Leucopenia (44%). Conclusion: Thus from our study we have concluded that toxicity of High Dose Methotrexate can be minimized to great extent by adequate hydration/ Alkalinization, Leucovorin doses, accurate dose of Anti emetics and frequent monitoring of Urine pH, Serum Creatinine, Complete Blood Count as to detect any toxicity and acute management of the toxicity.

show abstract

Clinician preference and comparison of the efficacy of ondansetron, granisetron, and palonosetron in preventing chemotherapy-induced nausea and vomiting among children receiving moderate or highly emetogenic chemotherapy

Bansal,

Agrawal,

Kohli

et al. 2023

Pediatric Hematology Oncology Journal

View full text Add to dashboard Cite

Randomized Double Blind Trial to Compare the Efficacy of Granisetron And Ondansetron in Controlling Emesis in Children with Acute Lymphoblastic Leukemia

Cited by 4 publications

References 20 publications

The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients

The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients

A Retrospective Analysis of Toxicity Profile in Pediatric Patients with all Receiving High Dose Methotrexete

Clinician preference and comparison of the efficacy of ondansetron, granisetron, and palonosetron in preventing chemotherapy-induced nausea and vomiting among children receiving moderate or highly emetogenic chemotherapy

Contact Info

Product

Resources

About